Get the Stockscreener App
7.16
8.81%
0.58
After Hours:
7.11
-0.05
-0.70%
Clene Inc stock is traded at $7.16, with a volume of 532.54K.
It is up +8.81% in the last 24 hours and up +24.31% over the past month.
Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. It developed an electro-crystal-chemistry drug development platform that enables the production of concentrated, stable, clean-surfaced nanocrystal suspensions. It operates in one segment the development and commercialization of dietary supplements (Supplements). Products includes CNM-Au8, CNM-ZnA, CNM-AgZn17, rMetx, KHC46.
See More
Previous Close:
$6.58
Open:
$6.61
24h Volume:
532.54K
Relative Volume:
1.22
Market Cap:
$84.33M
Revenue:
$200.00K
Net Income/Loss:
$-26.17M
P/E Ratio:
-2.7564
EPS:
-2.5976
Net Cash Flow:
$-18.63M
1W Performance:
+23.45%
1M Performance:
+24.31%
6M Performance:
-22.59%
1Y Performance:
+151.23%
1-Day Range:
$6.6001
$7.50
1-Week Range:
$5.69
$8.67
52-Week Range:
$2.2801
$13.50
Clene Inc Stock (CLNN) Company Profile
Name
Clene Inc
Sector
Industry
Phone
801-676-9695
Address
6550 SOUTH MILLROCK DRIVE, SUITE G50, SALT LAKE CITY
Compare CLNN vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CLNN
Clene Inc
|
7.16 | 77.50M | 200.00K | -26.17M | -18.63M | -2.5976 |
VRTX
Vertex Pharmaceuticals Inc
|
427.65 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
721.05 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
807.55 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.00 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
313.32 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Clene Inc Stock (CLNN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-04-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Jul-18-22 | Initiated | H.C. Wainwright | Buy |
| May-02-22 | Initiated | Canaccord Genuity | Buy |
| Sep-28-21 | Initiated | Oppenheimer | Outperform |
Clene Inc Stock (CLNN) Latest News
Clene Conference: CEO Says FDA Minutes Suggest CNM-Au8 Data Could Support ALS NDA Filing - Yahoo Finance
Analysts Are Bullish on Top Consumer Goods Stocks: BRC (BRCC), Clene (CLNN) - The Globe and Mail
CLNN stock rises 8% – here’s what the FDA update means for Clene’s ALS treatment - MSN
MSN Money - MSN
Clene Inc. Announces Underwriting Agreement for 1,000,000 Shares of Common Stock on Nasdaq - Minichart
Clene Announces $7 Million Registered Direct Equity Offering - TipRanks
Ugwumba Chidozie sells $530,439 in Clene Inc. shares By Investing.com - Investing.com Australia
Ugwumba Chidozie sells $530,439 in Clene Inc. shares - Investing.com
SymBiosis II LLC, major Clene (NASDAQ: CLNN) holder, sells 78,679 shares - Stock Titan
Clene Incannounces common stock offeringSEC filing - marketscreener.com
Clene Inc. (NASDAQ: CLNN) files preliminary prospectus for common stock offering - Stock Titan
Clene (NASDAQ: CLNN) prices $7M stock sale to fund CNM-Au8 work - Stock Titan
Clene plans CNM-Au8 filing for accelerated approval in ALS - ALS News Today
Clene Stock Jumps After FDA Opens Door To Accelerated Approval For ALS Drug - Sahm
Clene Announces $7 Million Underwritten Offering of Common Stock - Investing News Network
Clene stock tumbles after pricing $7M stock offering By Investing.com - Investing.com Australia
Clene stock tumbles after pricing $7M stock offering - Investing.com UK
Clene announces $7 million underwritten offering of common stock - marketscreener.com
Clene to Present at Upcoming May Conferences - Investing News Network
Clene prices $7M stock offering to fund drug development - Investing.com
Clene prices $7M stock offering to fund drug development By Investing.com - Investing.com Australia
Clene Inc. Announces Pricing of $7 Million Registered Direct Offering of Common Stock - Quiver Quantitative
Clene sells 1M shares to fund ALS drug filing and Phase 3 trial - Stock Titan
Clene lines up May 6 webcast and New York investor meetings May 7 - Stock Titan
Symbiosis II LLC lists CLNN sales (NASDAQ: CLNN) including 67,991-share lot - Stock Titan
CLNN Maintained by D. Boral Capital -- Price Target Stays at $23 - GuruFocus
Clene Price Target Maintained With a $23.00/Share by D. Boral Capital - Moomoo
Clene Is Maintained at Buy by D. Boral Capital - Moomoo
CLNN Stock Holds Range As Insider Ownership Shifts - StocksToTrade
Clene provides update on NDA for ALS following Type C meeting with FDA - TipRanks
Clene Advances Towards NDA Submission for ALS Treatment (CLNN) - GuruFocus
Clene plans ALS drug application after FDA meeting By Investing.com - Investing.com South Africa
CLNN Stock Rises 8% – Here’s What The FDA Update Means For Clene’s ALS Treatment - Stocktwits
Clene Stock Jumps After FDA Opens Door to Fast-Track ALS Drug Filing - TechStock²
Clene plans ALS drug application after FDA meeting - Investing.com UK
Clene Inc. to Submit Accelerated Approval NDA for ALS Drug CNM-Au8 Following Positive FDA Meeting - Minichart
CLNN Stock Holds Range As Insider Activity Draws Focus - timothysykes.com
After Successful FDA Meeting, Clene Filing Accelerated Approval NDA for ALS - Investing News Network
Clene Advances CNM-Au8 Toward Accelerated ALS Approval - TipRanks
Clene stock surges 20% after FDA meeting on ALS drug approval By Investing.com - Investing.com South Africa
Clene plans ALS drug filing after FDA says data may support faster review - Stock Titan
Clene stock surges 20% after FDA meeting on ALS drug approval - Investing.com
After successful FDA meeting, Clene filing accelerated approval NDA for ALS - marketscreener.com
Clene (NASDAQ: CLNN) to file accelerated ALS drug NDA in 2026 - Stock Titan
Clene Inc. (NASDAQ:CLNN) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Major Clene Investor Quietly Unloads a Chunk of Shares - TipRanks
Chidozie Ugwumba Sells 12,170 Shares of Clene (NASDAQ:CLNN) Stock - MarketBeat
Clene (NASDAQ:CLNN) Major Shareholder Chidozie Ugwumba Sells 5,736 Shares - MarketBeat
Clene Inc. 10% owner Chidozie Ugwumba sells $112,778 in common stock - Investing.com Canada
Clene Inc Stock (CLNN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.77%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):